Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) held its annual general and special meeting on February 9, 2023, where 6,663,370 common shares, representing 42.94% of the total shares, were voted. Shareholders approved all proposed resolutions, which included appointing MNP LLP as auditors, electing new directors, and approving the new omnibus equity incentive plan. The Omnibus Plan is pending final approval from the Toronto Stock Exchange. A formal report of the voting results will be filed on SEDAR.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced positive feedback from the FDA for its pivotal study of Bria-IMT™ combined with a checkpoint inhibitor aimed at treating advanced metastatic breast cancer. The company aims to accelerate commercialization through this pivotal study, potentially leading to a Biologics License Application. Eligible patients are those who have exhausted approved therapies, with a primary endpoint focused on survival improvement. BriaCell has $37 million in cash, allowing it to proceed without additional financing. The company also plans to initiate a Bria-OTS™ personalized treatment program in 2023.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced measures to combat alleged illegal trading that has possibly depressed its share price. The Company suspects collusion aimed at undermining shareholder interests. In response, BriaCell is considering legal action against those involved in these practices. This initiative reflects the Company’s commitment to protecting its investors and advancing its immunotherapy treatments for cancer. BriaCell aims to establish itself as a leader in the immuno-oncology space, emphasizing the importance of supportive investors in its ongoing development efforts.

BriaCell has received positive feedback from the FDA following its End of Phase II meeting regarding its lead candidate, Bria-IMT™, in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The FDA's agreement on primary endpoints and study design paves the way for a pivotal clinical study targeting patients with no approved treatment options. Success in this registration study could lead to a Biologics License Application (BLA) for commercialization of this innovative immunotherapy. This milestone reflects BriaCell's commitment to advancing its immuno-oncology programs.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has secured a new US patent for its personalized off-the-shelf cancer immunotherapy technology, extending protection until May 2040. The company plans to commence its Bria-OTS™ clinical study in the first half of 2023, as guided by the FDA. Additionally, two new clinical sites, Carle Cancer Institute in Illinois and American Oncology Network in Maryland, have been added for the Phase II Bria-IMT™ study, aimed at improving treatment access for advanced breast cancer patients.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented promising clinical data at the 2022 San Antonio Breast Cancer Symposium for its Bria-IMT™ combination regimen targeting advanced metastatic breast cancer patients. Positive outcomes included tumor shrinkage, disease control, and improved progression-free survival. Patients reported better quality of life and less pain. The treatment demonstrated excellent tolerability, with no dose-limiting toxicities. Future studies aim to validate these findings further and explore the potential of the Bria-OTS2.0 personalized immunotherapy.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a collaboration with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW), focusing on AI-driven antibody discovery for cancer therapies. BioStrand, a subsidiary of IPA, will utilize its LENSai™ software to create clinical molecules. The partnership includes an upfront payment of US$500,000 for BioStrand, along with additional success-based milestones. This initiative aims to enhance the efficiency of developing targeted treatments, aligning with the long-term vision of advancing precision medicine.

BriaCell Therapeutics Corp. (BCTX, BCTXW) announced promising initial efficacy results from its phase I/IIaa clinical trial of Bria-IMT™ combined with Incyte’s retifanlimab for advanced breast cancer. Presenting at the SITC annual meeting, they reported a 70% disease control rate and tumor shrinkage in 70% of 12 patients, all of whom had previously failed multiple therapies. The company is in talks with the FDA to progress to pivotal studies, aiming for broader patient access to this innovative treatment.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced promising results from a Phase I/IIa study involving 12 advanced breast cancer patients treated with Bria-IMT™ and Incyte's retifanlimab. The study showed that 70% of patients achieved either disease control or progression-free survival, with a disease control rate of 57%. These results are significant as the patients had previously undergone at least two unsuccessful therapies. The regimen was well tolerated, and BriaCell has received FDA fast track designation for the study.